# KDIGO Health States Classification for Chronic Kidney Disease (CKD)

## Overview

KDIGO (Kidney Disease: Improving Global Outcomes) is the international organization that publishes evidence-based clinical practice guidelines for kidney disease. The KDIGO CKD classification system categorizes patients into different health states based on two key parameters:

1. **GFR Categories** (G1-G5) - Based on kidney function (eGFR)
2. **Albuminuria Categories** (A1-A3) - Based on protein in urine (uACR)

These two dimensions create a **risk matrix** that determines disease severity and prognosis.

---

## 1. GFR CATEGORIES (Kidney Function)

GFR (Glomerular Filtration Rate) measures how well the kidneys filter blood. It's reported as eGFR (estimated GFR) in mL/min/1.73mÂ².

### G1: Normal or High Kidney Function
- **eGFR:** â‰¥90 mL/min/1.73mÂ²
- **Description:** Normal kidney function OR high filtration (hyperfiltration)
- **CKD Diagnosis:** Only if other kidney damage present (proteinuria, structural abnormalities, etc.)
- **Clinical Significance:** 
  - May be normal in young, healthy individuals
  - In diabetics, may indicate hyperfiltration (early sign of kidney stress)
  - Not CKD unless accompanied by kidney damage markers

### G2: Mildly Decreased Kidney Function
- **eGFR:** 60-89 mL/min/1.73mÂ²
- **Description:** Mild reduction in kidney function
- **CKD Diagnosis:** Only if other kidney damage present
- **Clinical Significance:**
  - Often normal aging in elderly (>60 years)
  - CKD if accompanied by albuminuria or structural damage
  - Generally asymptomatic
  - May be considered CKD in younger patients

### G3a: Mild to Moderate Decrease
- **eGFR:** 45-59 mL/min/1.73mÂ²
- **Description:** Mild to moderately decreased kidney function
- **CKD Stage:** 3a
- **Clinical Significance:**
  - Definite CKD regardless of other markers
  - Risk of complications begins to increase
  - May start to see metabolic complications
  - Usually still asymptomatic
  - Medication dose adjustments may be needed

### G3b: Moderate to Severe Decrease
- **eGFR:** 30-44 mL/min/1.73mÂ²
- **Description:** Moderately to severely decreased kidney function
- **CKD Stage:** 3b
- **Clinical Significance:**
  - Higher risk category than G3a
  - Increased risk of cardiovascular events
  - Metabolic complications more common (anemia, bone disease)
  - Symptoms may begin to appear
  - Nephrology referral recommended
  - More aggressive management needed

### G4: Severely Decreased Kidney Function
- **eGFR:** 15-29 mL/min/1.73mÂ²
- **Description:** Severe reduction in kidney function
- **CKD Stage:** 4
- **Clinical Significance:**
  - Pre-dialysis stage
  - Significant symptoms often present (fatigue, fluid retention, uremia)
  - Multiple complications (anemia, bone disease, hyperkalemia, acidosis)
  - **MANDATORY nephrology involvement**
  - Dialysis planning and education should begin
  - Vascular access creation considered
  - Transplant evaluation if appropriate

### G5: Kidney Failure (ESRD)
- **eGFR:** <15 mL/min/1.73mÂ²
- **Description:** Kidney failure / End-Stage Renal Disease (ESRD)
- **CKD Stage:** 5
- **Clinical Significance:**
  - Kidneys functioning at <15% of normal
  - Dialysis or transplant usually required to sustain life
  - Severe uremic symptoms without dialysis
  - May be designated G5D if on dialysis
  - Quality of life significantly impaired without renal replacement therapy

---

## 2. ALBUMINURIA CATEGORIES (Kidney Damage)

Albuminuria measures protein (specifically albumin) leaking into urine. Measured as uACR (urine albumin-to-creatinine ratio) in mg/g.

### A1: Normal to Mildly Increased
- **uACR:** <30 mg/g (or <3 mg/mmol)
- **Alternative Names:** 
  - Normal albuminuria
  - Normoalbuminuria
- **Description:** Normal or minimally elevated albumin in urine
- **Clinical Significance:**
  - Normal kidney filtration barrier
  - Low risk of progression
  - No specific treatment needed for albuminuria
  - Continue routine monitoring

### A2: Moderately Increased
- **uACR:** 30-300 mg/g (or 3-30 mg/mmol)
- **Alternative Names:**
  - Microalbuminuria (older term)
  - Moderately increased albuminuria
- **Description:** Moderate protein leak indicating kidney damage
- **Clinical Significance:**
  - Early sign of kidney damage
  - Independent risk factor for CKD progression
  - Independent risk factor for cardiovascular disease
  - **Treatment recommended:**
    - RAS inhibitors (ACE-I or ARB)
    - SGLT2 inhibitors if diabetic or eGFR 20-75
    - Blood pressure control (<130/80 mmHg)
    - Diabetes control (HbA1c <7%)
  - More frequent monitoring needed

### A3: Severely Increased
- **uACR:** >300 mg/g (or >30 mg/mmol)
- **Alternative Names:**
  - Macroalbuminuria (older term)
  - Severely increased albuminuria
  - Nephrotic-range proteinuria (if >3000 mg/g)
- **Description:** Heavy protein leak indicating significant kidney damage
- **Clinical Significance:**
  - High risk of rapid CKD progression
  - Very high cardiovascular risk
  - May indicate glomerular disease
  - **Aggressive treatment required:**
    - Maximum RAS inhibition (ACE-I or ARB at max dose)
    - SGLT2 inhibitor strongly recommended
    - Strict BP control (<130/80 or even lower)
    - Consider nephrology referral
    - May need kidney biopsy if cause unclear
  - If nephrotic range (>3000 mg/g): specialized care essential

---

## 3. KDIGO RISK MATRIX: Combined Classification

The combination of GFR and Albuminuria categories creates a **risk stratification matrix**:

```
                           ALBUMINURIA CATEGORIES
                    A1              A2              A3
                  (<30 mg/g)    (30-300 mg/g)   (>300 mg/g)
            â”Œâ”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”
G1 (â‰¥90)    â”‚   LOW RISK      MODERATE RISK    HIGH RISK      â”‚
            â”‚   (Green)       (Yellow)         (Orange)       â”‚
G2 (60-89)  â”‚   LOW RISK      MODERATE RISK    HIGH RISK      â”‚
            â”‚   (Green)       (Yellow)         (Orange)       â”‚
G3a (45-59) â”‚   MODERATE      HIGH RISK        VERY HIGH RISK â”‚
            â”‚   (Yellow)      (Orange)         (Red)          â”‚
G3b (30-44) â”‚   HIGH RISK     VERY HIGH RISK   VERY HIGH RISK â”‚
            â”‚   (Orange)      (Red)            (Red)          â”‚
G4 (15-29)  â”‚   VERY HIGH     VERY HIGH RISK   VERY HIGH RISK â”‚
            â”‚   (Red)         (Red)            (Red)          â”‚
G5 (<15)    â”‚   VERY HIGH     VERY HIGH RISK   VERY HIGH RISK â”‚
            â”‚   (Red)         (Red)            (Red)          â”‚
            â””â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”˜
```

### Risk Level Definitions

**ğŸŸ¢ GREEN (Low Risk)**
- Categories: G1-A1, G2-A1
- Prognosis: Excellent
- Progression Risk: Minimal
- Management: Routine screening, address risk factors
- Monitoring: Annual

**ğŸŸ¡ YELLOW (Moderately Increased Risk)**
- Categories: G1-A2, G2-A2, G3a-A1
- Prognosis: Good with management
- Progression Risk: Low to moderate
- Management: Treat albuminuria, BP control, address risk factors
- Monitoring: Every 6-12 months

**ğŸŸ  ORANGE (High Risk)**
- Categories: G1-A3, G2-A3, G3a-A2, G3b-A1
- Prognosis: Guarded without intervention
- Progression Risk: Moderate to high
- Management: Aggressive treatment, nephrology consideration
- Monitoring: Every 3-6 months

**ğŸ”´ RED (Very High Risk)**
- Categories: G3a-A3, G3b-A2, G3b-A3, G4-any A, G5-any A
- Prognosis: Poor without intervention
- Progression Risk: High to very high
- Management: Intensive treatment, nephrology mandatory
- Monitoring: Every 1-3 months

---

## 4. DETAILED HEALTH STATES (18 Possible Combinations)

### Low Risk States (Green) - 2 combinations

**G1-A1: Normal Kidneys**
- eGFR â‰¥90 + uACR <30
- Completely normal kidney function and structure
- No CKD (unless other damage markers present)
- Action: None, routine health maintenance

**G2-A1: Mild Decrease, No Damage**
- eGFR 60-89 + uACR <30
- May be normal aging (especially age >60)
- Not CKD unless other markers present
- Action: Monitor risk factors

### Moderately Increased Risk (Yellow) - 3 combinations

**G1-A2: Normal Function, Moderate Damage**
- eGFR â‰¥90 + uACR 30-300
- CKD Stage 1
- Early kidney damage with preserved function
- Common in early diabetic kidney disease
- Action: RAS inhibitor, SGLT2i if diabetic, BP control

**G2-A2: Mild Decrease with Moderate Damage**
- eGFR 60-89 + uACR 30-300
- CKD Stage 2
- Progressive kidney damage
- Action: Same as G1-A2, closer monitoring

**G3a-A1: Moderate Function Loss, No Proteinuria**
- eGFR 45-59 + uACR <30
- CKD Stage 3a
- May be primary GFR loss (aging, hypertension)
- Action: Address risk factors, medication dose adjustments

### High Risk States (Orange) - 4 combinations

**G1-A3: Normal Function, Heavy Damage**
- eGFR â‰¥90 + uACR >300
- CKD Stage 1 (severe)
- Glomerular disease likely
- Rapid progression risk
- Action: Nephrology referral, consider biopsy, aggressive treatment

**G2-A3: Mild Decrease with Heavy Damage**
- eGFR 60-89 + uACR >300
- CKD Stage 2 (severe)
- Progressive glomerular disease
- Action: Same as G1-A3

**G3a-A2: Moderate Loss with Moderate Damage**
- eGFR 45-59 + uACR 30-300
- CKD Stage 3a (moderate damage)
- Dual pathology (function + structure)
- Action: Aggressive treatment, closer monitoring

**G3b-A1: Severe Function Loss, No Proteinuria**
- eGFR 30-44 + uACR <30
- CKD Stage 3b
- Significant kidney impairment
- Action: Nephrology referral, prepare for progression

### Very High Risk States (Red) - 9 combinations

**G3a-A3: Moderate Loss with Heavy Damage**
- eGFR 45-59 + uACR >300
- CKD Stage 3a (severe)
- High progression risk
- Action: Nephrology referral, intensive treatment

**G3b-A2: Severe Loss with Moderate Damage**
- eGFR 30-44 + uACR 30-300
- CKD Stage 3b (moderate damage)
- Multiple complications likely
- Action: Nephrology management, close monitoring

**G3b-A3: Severe Loss with Heavy Damage**
- eGFR 30-44 + uACR >300
- CKD Stage 3b (severe)
- Very high progression risk
- Action: Intensive nephrology care

**G4-A1: Very Severe Loss, No Proteinuria**
- eGFR 15-29 + uACR <30
- CKD Stage 4
- Pre-dialysis stage
- Action: Dialysis planning, vascular access

**G4-A2: Very Severe Loss with Moderate Damage**
- eGFR 15-29 + uACR 30-300
- CKD Stage 4 (moderate damage)
- Action: Same as G4-A1, more aggressive

**G4-A3: Very Severe Loss with Heavy Damage**
- eGFR 15-29 + uACR >300
- CKD Stage 4 (severe)
- Highest progression risk in G4
- Action: Urgent dialysis preparation

**G5-A1: Kidney Failure, No Proteinuria**
- eGFR <15 + uACR <30
- CKD Stage 5 (ESRD)
- Action: Dialysis or transplant

**G5-A2: Kidney Failure with Moderate Damage**
- eGFR <15 + uACR 30-300
- CKD Stage 5 (ESRD)
- Action: Same as G5-A1

**G5-A3: Kidney Failure with Heavy Damage**
- eGFR <15 + uACR >300
- CKD Stage 5 (ESRD, severe)
- Worst prognosis of all categories
- Action: Dialysis or transplant

---

## 5. CLINICAL APPLICATION OF KDIGO CLASSIFICATION

### For Risk Assessment

The KDIGO classification helps determine:
1. **Prognosis** - Risk of kidney failure
2. **Cardiovascular risk** - Independent predictor
3. **Mortality risk** - All-cause mortality
4. **Monitoring frequency** - How often to check labs
5. **Treatment intensity** - How aggressive to be
6. **Referral timing** - When to involve nephrology

### For Treatment Decisions

**Based on GFR Category:**
- **G1-G2:** Focus on prevention, address risk factors
- **G3a:** Medication dose adjustments, closer monitoring
- **G3b:** Nephrology referral, prepare for complications
- **G4:** Mandatory nephrology, dialysis planning
- **G5:** Renal replacement therapy

**Based on Albuminuria Category:**
- **A1:** No specific treatment for albuminuria
- **A2:** RAS inhibitor, SGLT2i consideration
- **A3:** Maximum RAS inhibition, SGLT2i strongly recommended

### For Monitoring Frequency

| Risk Level | GFR Monitoring | Albuminuria Check | BP Monitoring |
|------------|----------------|-------------------|---------------|
| Low (Green) | Annually | Annually | Per guidelines |
| Moderate (Yellow) | 6-12 months | 6-12 months | Every visit |
| High (Orange) | 3-6 months | 3-6 months | Every visit |
| Very High (Red) | 1-3 months | 3-6 months | Every visit |

---

## 6. PROGRESSION PATTERNS

### How Patients Move Between States

**Typical Progression (without treatment):**
1. **G1-A2** â†’ G2-A2 â†’ G3a-A2 â†’ G3b-A3 â†’ G4-A3 â†’ G5-A3
   - Both GFR declines AND albuminuria worsens
   - Most common in diabetic kidney disease

2. **G1-A1** â†’ G2-A1 â†’ G3a-A1 â†’ G3b-A1 â†’ G4-A1
   - GFR declines but no proteinuria
   - Common in aging, hypertensive nephrosclerosis

3. **G2-A1** â†’ G2-A2 â†’ G2-A3 â†’ G3a-A3 â†’ G3b-A3
   - Function preserved initially, damage progresses
   - Common in glomerular diseases

**Treatment Goal:**
- **Stabilize** the current state
- **Slow** progression to next worse state
- **Reverse** albuminuria category if possible (A3â†’A2â†’A1)
- **Prevent** movement into red zones

### Rate of Progression

**Without Treatment:**
- Low risk: ~0-1 mL/min/year decline
- Moderate risk: ~2-4 mL/min/year decline
- High risk: ~4-8 mL/min/year decline
- Very high risk: >8 mL/min/year decline

**With Optimal Treatment (RAS-I + SGLT2i):**
- Can reduce progression by 30-50%
- May stabilize or even improve GFR
- Can reduce albuminuria by 30-50%
- Some patients move from A3â†’A2â†’A1

---

## 7. SPECIAL CONSIDERATIONS

### Acute Kidney Injury (AKI) vs CKD

KDIGO also has AKI classification:
- **Stage 1:** Creatinine 1.5-1.9Ã— baseline OR urine <0.5 mL/kg/h for 6-12h
- **Stage 2:** Creatinine 2.0-2.9Ã— baseline OR urine <0.5 mL/kg/h for â‰¥12h
- **Stage 3:** Creatinine â‰¥3Ã— baseline OR urine <0.3 mL/kg/h for â‰¥24h OR dialysis

Important: AKI can occur on top of any CKD stage (e.g., "CKD G3b with AKI Stage 2")

### CKD-MBD (Mineral and Bone Disorder)

Additional classification for complications:
- Abnormal calcium, phosphorus, PTH, vitamin D
- Becomes important in G3b-G5
- Requires specific monitoring and treatment

### Other Causes of CKD

KDIGO classification applies regardless of cause:
- Diabetic kidney disease
- Hypertensive nephrosclerosis
- Glomerulonephritis
- Polycystic kidney disease
- Obstructive uropathy
- Drug-induced kidney disease

---

## 8. TREATMENT TARGETS BY KDIGO CATEGORY

### Blood Pressure Targets
- **No proteinuria (A1):** <140/90 mmHg
- **With proteinuria (A2-A3):** <130/80 mmHg
- **With diabetes + proteinuria:** <130/80 mmHg

### Diabetes Control
- **G1-G3a:** HbA1c <7%
- **G3b-G5:** HbA1c <7.5% (avoid hypoglycemia)

### Lipid Management
- **G1-G2:** Per CV risk
- **G3a-G5:** Statin recommended for all adults

### Medication Management by GFR
- **G1-G2:** No dose adjustments
- **G3a:** Some medications need adjustment
- **G3b:** Many medications need adjustment
- **G4-G5:** Most medications need adjustment or avoidance

---

## SUMMARY TABLE

| KDIGO Category | eGFR (mL/min) | uACR (mg/g) | Risk Level | CKD Stage | Key Actions |
|----------------|---------------|-------------|------------|-----------|-------------|
| G1-A1 | â‰¥90 | <30 | Low | - | Routine care |
| G1-A2 | â‰¥90 | 30-300 | Moderate | 1 | RAS-I, SGLT2i |
| G1-A3 | â‰¥90 | >300 | High | 1 | Nephrology referral |
| G2-A1 | 60-89 | <30 | Low | - | Monitor |
| G2-A2 | 60-89 | 30-300 | Moderate | 2 | RAS-I, SGLT2i |
| G2-A3 | 60-89 | >300 | High | 2 | Nephrology referral |
| G3a-A1 | 45-59 | <30 | Moderate | 3a | Medication adjustment |
| G3a-A2 | 45-59 | 30-300 | High | 3a | RAS-I, SGLT2i |
| G3a-A3 | 45-59 | >300 | Very High | 3a | Nephrology care |
| G3b-A1 | 30-44 | <30 | High | 3b | Nephrology referral |
| G3b-A2 | 30-44 | 30-300 | Very High | 3b | Intensive care |
| G3b-A3 | 30-44 | >300 | Very High | 3b | Intensive care |
| G4-any | 15-29 | Any | Very High | 4 | Dialysis planning |
| G5-any | <15 | Any | Very High | 5 | Dialysis/transplant |

---

## REFERENCES

1. KDIGO 2024 Clinical Practice Guideline for the Evaluation and Management of Chronic Kidney Disease
2. KDIGO 2012 CKD Classification and Risk Assessment
3. International Society of Nephrology - KDIGO Guidelines

---

**Note:** The KDIGO classification is the international standard used worldwide for CKD diagnosis, staging, prognosis, and management. All modern CKD care should be based on this classification system.
